Neurogene

Neurogene

Edit info

  • Founded: 2018
  • Location: New York, NY
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Batten disease
  • Drug types: GEN, NEU, PED
  • Lead product: NGN-101
  • Funding: $68M A Feb 2019


neurogene.com

linkedin.com

job board


Drug notes:

NGN-401 Clin1/Clin2 Rett syndrome; NGN-201 Clin0 Krabbe disease; NGN-402 RD neurodevelopmental condition

About:

Neurogene is a clinical-stage biotech company developing life-changing gene therapies for patients battling devastating neurological diseases. Their mission is to transform these complex and often incurable conditions into treatable ones. Neurogene utilizes adeno-associated virus (AAV) vectors, in addition to other viral and non-viral platforms to deliver functional copies of genes or gene editing tools directly into a patients' cells. Their proprietary platform, EXACT allows for precise control over transgene expression, minimizing potential side effects associated with conventional gene therapy approaches. Neurogene has constructed a state-of-the-art manufacturing facility to support their clinical development activities, ensuring quality and potentially expediting clinical trials.

Jobs:

Neurogene
Manager, Clinical Supplies
Houston, TX|20 days ago
Apply
Neurogene
Quality Assurance Compliance Manager
United States|20 days ago
Neurogene
Associate Director, Compensation and Benefits
New York, United States|20 days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com